Haemonetics Corp

Latest Results (03.10.2025):

Haemonetics Corporation reported strong financial results for the third quarter of fiscal 2025, demonstrating growth in revenue, earnings, and cash flow. The company also updated its fiscal 2025 guidance, reflecting continued confidence in its strategic initiatives and market positioning.

Revenue Growth

In the third quarter of fiscal 2025, Haemonetics reported a revenue increase of $349 million, representing a 4% growth compared to the same period last year. Year-to-date revenue reached $1,030 million, up by 7%.

Earnings Per Share

Earnings per diluted share rose to $0.74 in the third quarter, up from $0.61 in fiscal 2024. Adjusted earnings per diluted share increased to $1.19, a 14.4% growth year-over-year.

Gross Margin Improvement

Haemonetics achieved a gross margin of 55.5% in the third quarter of fiscal 2025, up from 52.9% in the previous year. This improvement was driven by higher-margin product volumes and pricing benefits across all business units.

Operating Income and Margin

Operating income surged to $59.0 million, with an operating margin of 16.9%, compared to $46.0 million and 13.7% respectively in the third quarter of fiscal 2024. Adjusted operating income also saw a significant increase of 21.9%.

Cash Flow Generation

Cash flow from operating activities reached $44 million, and free cash flow stood at $30 million for the third quarter of fiscal 2025. Both metrics showed substantial improvement compared to the same period last year.

Updated Fiscal 2025 Guidance

Haemonetics updated its fiscal 2025 guidance, anticipating continued revenue growth and margin expansion. The company projects reported revenue growth between 5-7%, with adjusted earnings per diluted share ranging from $4.50 to $4.70 and free cash flow expected between $120 million and $140 million.